the aggressive of cancer. therapy morning, as to platform At that our cancer focused Treating some XX-plus of a standards forms everyone. use on we with good Ingrid, you, most Novocure, evolving care our are of mission research supports Fields in Tumor and survival scientific the extend and Thank we a of Tumor in totality Treating can the indications. multitude belief of Fields safely years of
opportunities and have patients ease-of-use efficacy improving and also We to enhance numerous to further for therapy our explore caregivers. our
clinical is yet continues robust Our trial pipeline opportunities grow and be with research explored. to organic to
extensive that our therapy expandable expanding that are we intellectual have defend. have ago, We portfolio Since established years founding over we a XX repeatable. property is consistently an will cancer and unique, rigorously and model business
Our the business is approaching months, cash our international supporting is investments XX to we and growth. key out a future in the next are With is organization. generative Novocure to point making set read GBM multiple significant and inflection believe we patients trials late-stage generate for
As and cash in in provided our efforts novel and our of fundamentals grow are Company. before are help our by opportunities cancer the summary, energized business we product with hand, in investing $XXX more the In to development to on need. to therapy over and and the in we our aggressively patients many more patients close on strong, by many to milestones are we pipeline million bring these us stability
an and our Before of the enrolled Phase have would forward major ovarian discuss for cancer. our for last program is all of a for treatment pivotal that I achievement the we trial is quarterly we trial those our step announce clinical to platinum-resistant INNOVATE-X like involved. important results, This X in patient
first, our will from we business. the the Asaf In will momentarily. provide in updates more quarter detail steps, next GBM call, core on discuss today’s
clinical We recent progress. our then development will turn to
business sustainable power will the underline and model. flexibility afforded our we by financial Finally,
in future investment Our our GBM business growth continues initiatives. aggressive fuel to
development, the we in This year on of million total revenue million, total therapy. first three XX% to generated research $XXX global $XXX.X invested during all amount We active quarters nearly the more and the in X,XXX with our $XX million of than in patients ended the quarter quarter, bringing and over XXXX. investment in R&D invested
GBM focuses population markets. engagement our on eligible increasing Our growth our to penetration of is broadening through with patient our believe geographic paramount as penetration centers label as in further academic our footprint and efforts. key strategy current expansion well We
GBM a see sizable where We academic underpenetrated. have identified the are we population portion centers, which of
We expand with touch points centers. are pursuing and increase opportunities to these
we with Our Dr. teams multiple Also, investigator-sponsored initiation have several trials opened multiple scheduled. at such key centers launched site academic as have clinical trials
physicians, all we with and opportunities ebb Soltys with hospital These ongoing staffing hypofractionated have levels, delayed hands-on engagement study I cancer wrought to of population. COVID-XX their case time. and reduced ability some experience our adopted Both COVID-XX at reduced volumes. starting all and surgeries business. plus interact Policies have trials TTFields. clinical at hospitals would Stanford the by for effects infections Broadly, commercial loads use challenges flow unique the investigator-sponsored academic case prevent with the at impacts be offer in to TTFields patient affect seen if to University, chemoradiation mention can of which by our did the manage ideal patient examining oncologists. practitioners on pandemic, the COVID I our remiss pandemic not trials regionally of the Optune stress patients of and
shielded In announced and GBM, provide to situations to study quarter. to for Fields our atezolizumab anti-PD-LX new be from these of Outside have environment Preclinical to and for all use result are of this several immune agents cancer. who make the with together the patients ductal in treatment the for Roche indication. with proved multiple unmet Treating nimble need trial together diagnosed in atezolizumab difficult immune failed immunotherapy first-line Tumor monitoring with increased with high therapy this everything inhibitors pancreas till the pancreatic the We innovative single-arm pancreatic trials believe a TTFields in notable benefit impact therapy Up of Tumor power to September, has penetrate, to clinical collaboration clinical use to checkpoint patients may an cancer. Treating control. the suggests now, TTFields We co-design metastatic tumor data of may the of doing achievements Fields be a in we daily and can announced we finally it.
FDA We with of the system excited breakthrough Also work NovoTTF-XXXT advanced this designation begin are treatment liver the quarter, leader. cancer. extremely our global for to granted another for device oncology the
review future for regulatory prioritized designation directly the interact submissions. As we and review a device Phase look X the ahead with process opportunity allows in of offers to experts cancer, through premarket breakthrough to liver trial FDA
Lab. We announced trial, with treatment of in studying enrollment gastric final the also patient our together partner, single-arm Zai cancer our EF-XX the
cancer one As of a common cancer a year. third is in median and reminder, most has approximately China poor prognosis gastric the survival rate overall with
completed Now and the release look to forward XXXX. analysis that beginning on enrollment, has are to track EF-XX data we process data in
so Daniel at efforts with milestone like milestone we XX internally Torres the that is Daniel to patient I’d Finally, you. four XXth summer, Daniel’s in Novocure celebrated share strong everyone birthday was trial and in are X This a in reminder important. his years first a with Chicago. wife recently why EF-XX ago. U.S. the his of to our enroll GBM celebrated children our Phase to
the to are survival cancer. with some for of forms most of patients diagnosed aggressive extend working We
pass updates. celebrate personally with now Novocure more being that, Daniel for loved will Daniel like and With I company like over Asaf, thank will So, patients a our the an milestones ambassador pipeline to ones. inspiration to can team. the who for their discuss I wonderful would our to call
Asaf?
